Courriel : bd@sidmexinovia.com
Téléphone : +918866862020
Heading 4
Heading 4
Heading 4
Heading 4
Heading 4
Heading 4
Heading 4
Heading 4
Heading 4
Heading 4
Heading 4
Heading 4
Kocitaf Tablet
Manufacturer/Marketed By : MYLAN PHARMACEUTICALS PVT LTD
$43.82 $19.17
Kocitaf Tablet contains the active ingredient Kocitaf Tablet. It is a combination of antiretroviral medication. Dolutegravir belongs to a class of antiretroviral drugs called integrase strand transfer inhibitors (INSTIs). Emtricitabine...
Collapsible text is perfect for longer content like paragraphs and descriptions. It's a great way to give people more information while keeping your layout clean. Link your text to anything, including an external website or a different page. You can set your text box to expand and collapse when people click, so they can read more or less info.
DOLUTEGRAVIR,EMTRICITABINE,TENOFOVIR ALAFENAMIDE
Active Pharmaceutical Ingredient
Kocitaf Tablet
43,82 $US
19,17 $US
Kocitaf Tablet contains the active ingredient Kocitaf Tablet. It is a combination of antiretroviral medication. Dolutegravir belongs to a class of antiretroviral drugs called integrase strand transfer inhibitors (INSTIs). Emtricitabine belongs to the class of medication called nucleoside reverse transcriptase inhibitor (NRTI), and tenofovir alafenamide belongs to the class called nucleotide reverse transcriptase inhibitor (NtRTI). It is combined with other medicines to treat human immunodeficiency virus (HIV-1) infection in adults and adolescents 12 years of age who weigh at least 35kg. The combination is available as a single tablet regimen, simplifying treatment by reducing the number of pills a person must take daily. This convenience improves medication adherence, ensuring individuals can consistently take their prescribed medication as scheduled. Do not take Kocitaf Tablet if anyone is allergic to it or its components. Get tested for HIV infection regularly while using this medicine. Missing a dose increases the risk of getting HIV infection. This medicine does not prevent other sexually transmitted infections (STIs). Patients should inform the physician if they have liver problems or liver disease, including hepatitis, kidney, and bone problems. This medication is not recommended to give in to children aged 11 years or under.
Active Pharmaceutical Ingredient
Uses
• HIV infection
Benefits
Kocitaf Tablet offers a highly effective and convenient treatment for HIV infection. It reduces viral load, maintains long-term viral suppression, and delays disease progression. A single-tablet regimen improves medication adherence. Additionally, it has an improved safety profile with a reduced risk of renal and bone toxicity.
Side Effects
Side effects are unwanted symptoms caused by medicines. Even though all drugs cause side effects, not everyone gets them.
Most Common Side Effects
• Headache
• Nausea
• Diarrhea
• Fatigue
• Insomnia
Common Side Effects
• Hepatitis B reactivation
• Increased risk of fracture
• Acute renal failure
How To Use
It is an orally available prescription drug. Your doctor will decide the dose and duration of Kocitaf Tablet based on the disease condition and other factors such as body weight and age. Always take this medicine as prescribed by your doctor. Take the tablet at the same time, with or without food. Do not break, chew, crush, or break the tablet. Swallow the whole tablet with a glass of water. If you have difficulty in swallowing the tablet whole, you can split it in half after consulting with your doctor.
Safety Advice
• Breast Feeding: Breastfeeding is not recommended in patients taking Kocitaf Tablet because the medicine passes into the breast milk in small amounts and may harm your baby. Do not breastfeed during the treatment.
• Alcohol: It is unknown whether Kocitaf Tablet is safe to be administered in patients with lung diseases. Inform your physician if you have any lung diseases before initiating the therapy.
• Liver: It is unknown whether Kocitaf Tablet is safe to be administered in patients with lung diseases. Inform your physician if you have any lung diseases before initiating the therapy.
• Lungs: Kocitaf Tablet should be cautiously administered in patients with liver diseases. Dose adjustments are necessary. However, inform your physician of any liver diseases before initiating the therapy.
• Driving: Kocitaf Tablet can cause dizziness. It is recommended to avoid driving and operating heavy machinery during the treatment.
• Pregnancy: There is limited information on the use of Kocitaf Tablet during pregnancy. Inform your physician if you are pregnant or planning to get pregnant during the treatment.
Disclaimer
Sidmex Inovia s'efforce de fournir des informations exactes et fiables. Cependant, l'ensemble du contenu de ce site web, y compris les descriptions et compositions des produits, est fourni à titre informatif uniquement et ne saurait se substituer à un avis, un diagnostic ou un traitement médical professionnel.
Il est conseillé aux utilisateurs de consulter un professionnel de santé qualifié avant toute décision médicale. Les informations fournies ne doivent pas être utilisées pour l'autodiagnostic ou l'automédication.
Tous les produits présentés sont exclusivement destinés aux professionnels (B2B) et aux demandes de renseignements en gros. Sidmex Inovia ne promeut pas la consommation directe par les particuliers et vise à soutenir, et non à remplacer, la relation entre le professionnel de santé et le patient.
Les noms de produits, marques et logos appartiennent à leurs propriétaires respectifs et leur utilisation n'implique aucune affiliation ni aucun parrainage. Sidmex Inovia décline toute responsabilité quant aux conséquences découlant de l'utilisation des informations fournies sur ce site web.